CVRx Inc. (CVRX)
16.17
1.13 (7.51%)
At close: Jan 14, 2025, 3:59 PM
16.30
0.80%
After-hours Jan 14, 2025, 04:01 PM EST
undefined% (undefined)
| Bid | 15 |
| Market Cap | 392.34M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.69 |
| PE Ratio (ttm) | -6.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 24 |
| Volume | 430,218 |
| Avg. Volume (20D) | 291,304 |
| Open | 16.02 |
| Previous Close | 15.04 |
| Day's Range | 15.88 - 16.87 |
| 52-Week Range | 6.40 - 29.23 |
| Beta | undefined |
About CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributo...
Industry Medical - Devices
Sector Healthcare
IPO Date Jun 30, 2021
Employees 200
Stock Exchange NASDAQ
Ticker Symbol CVRX
Website https://www.cvrx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CVRX stock is "Buy." The 12-month stock price forecast is $15.5, which is a decrease of -4.14% from the latest price.
Buy 85.71%
Hold 14.29%
Sell 0.00%
Next Earnings Release
CVRx Inc. is scheduled to release its earnings on Jan 27, 2025,
during market hours.
Analysts project revenue of $14.83M, reflecting a 31.18% YoY growth and earnings per share of -0.38, making a -13.64% decrease YoY.
Analysts project revenue of $14.83M, reflecting a 31.18% YoY growth and earnings per share of -0.38, making a -13.64% decrease YoY.
22 hours ago ·
Source
+7.38%
CVRx shares are trading higher after William Blair...
Unlock content with
Pro Subscription
1 day ago ·
Source
+6.14%
CVRx shares are trading higher after the company announced a year-over-year increase in Q4 and FY24 revenue results.
